ICMI 2015

T.112 Alterations of Intestinal Microbiota in Ulcerative Colitis Patients Treated with Sequential Antibiotic Combination and Faecal Microbiota Transplantation

Thursday, July 16, 2015
Grand Hall and Gallery, Ground Floor & 1st Floor (Maritim Hotel)
Dai Ishikawa, MD, phD , Juntendo University, Case Western Reserve University, Tokyo, Japan
Taro Osada, MD, phD , Juntendo University, Department of Gastroenterology, Tokyo, Japan
Takashi Sasaki, phD , Juntendo University, Department of Bacteriology, Tokyo, Japan
Kyoko Kuwahara-Arai, phD , Juntendo University, Department of Bacteriology, Tokyo, Japan
Keiichi Haga, MD , Juntendo University, Department of Gastroenterology, Tokyo, Japan
Tomoyoshi Shibuya, MD, phD , Juntendo University, Department of Gastroenterology, Tokyo, Japan
Tomohiro Kodani, MD, phD , Juntendo University, Department of Gastroenterology, Tokyo, Japan
Keiichi Hiramatsu, prof , Juntendo University, Department of Bacteriology, Tokyo, Japan
Sumio Watanabe, prof , Juntendo University, Department of Gastroenterology, Tokyo, Japan
Background:

Faecal microbiota transplantation (FMT) is emerging as a new therapeutic approach to restore normal function in the intestinal microbiota. In this study, we demonstrate alternations of intestinal microbiota and immune response in ulcerative colitis (UC) patients treated with a sequential therapy involving FMT following a combination of antibiotics.

Methods:

An antibiotic combination therapy with oral amoxicillin 1500mg/day, fosfomycin 3000mg/day and metronidazole 750mg/day was administered to UC patients for two weeks prior to FMT. Faecal microbiota of the donors and the patients after or before treatment (8 samples from each group, total 32 samples) were processed by sequencing and analysis of the 16S rRNA gene using a Next-generation sequencer MIseq (Illmina). Cytokine and chemokine in their blood samples were analyzed by Multiplex Immunoassays (Bioplex).

Results:

After a two-week-antibiotics therapy, the proportion of phylum Bacteroidetes significantly decreased (P<0.01), while the proportion of phylum Proteobacteria significantly increased (P<0.001). In half of the post-FMT patients, the proportion of phylum Bacteroidetes increased up to the level of donor. Further, along with the recovery of the Bacteroidetes strains after FMT, a trend toward an improvement in patients’ clinical symptoms score was noted.  

Conclusion:

To our knowledge, this is the first clinical study of a sequential therapy involving FMT following a combination of antibiotics. We hope that the strategy we have applied may serve as the basis for further progress in understanding how alterations of the intestinal microbiota and immune response may become an effective therapeutic strategy for UC patients.